IGEM:Harvard/2006/Fusion proteins

From OpenWetWare
Revision as of 07:20, 22 June 2006 by Lhahn (talk | contribs)
Jump to navigationJump to search

Protein domain BioBricks presentation

Cell surface targeting

General Fusion

  1. Klein BK, Hill SR, Devine CS, Rowold E, Smith CE, Galosy S, and Olins PO. Secretion of active bovine somatotropin in Escherichia coli. Biotechnology (N Y). 1991 Sep;9(9):869-72. DOI:10.1038/nbt0991-869 | PubMed ID:1367360 | HubMed [fusion1]
  2. We have expressed a chimeric protein, comprising the LamB secretion signal sequence fused to mature bovine somatotropin (bST), in Escherichia coli. Plasmid constructs with the recA promoter showed significant protein accumulation prior to induction and cell lysis occurred after induction. In contrast, the lacUV5 promoter was tightly regulated. With the lacUV5 promoter, temperature and inducer concentration had significant effects on the total amount of recombinant protein produced and the fraction processed to mature bST. Quantitation of bST from shake flask cultures showed that 1-2 micrograms/ml/OD550 could be released from the periplasm by osmotic shock. N-terminal sequence analysis of the purified protein indicated that the majority of the secreted bST was correctly processed. The bST present in the osmotic shock fraction was judged to be correctly folded by comigration with oxidized methionyl-bST standard on a non-reducing polyacrylamide gel and activity in a bovine liver radioreceptor assay. These results provide a rapid method to produce bST for use in structure-function studies.

    [fusion1ab]
  3. Utsumi R, Brissette RE, Rampersaud A, Forst SA, Oosawa K, and Inouye M. Activation of bacterial porin gene expression by a chimeric signal transducer in response to aspartate. Science. 1989 Sep 15;245(4923):1246-9. DOI:10.1126/science.2476847 | PubMed ID:2476847 | HubMed [fusion2]
  4. Moe GR, Bollag GE, and Koshland DE Jr. Transmembrane signaling by a chimera of the Escherichia coli aspartate receptor and the human insulin receptor. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5683-7. DOI:10.1073/pnas.86.15.5683 | PubMed ID:2548185 | HubMed [fusion3]
  5. Coulton JW, Mason P, Cameron DR, Carmel G, Jean R, and Rode HN. Protein fusions of beta-galactosidase to the ferrichrome-iron receptor of Escherichia coli K-12. J Bacteriol. 1986 Jan;165(1):181-92. DOI:10.1128/jb.165.1.181-192.1986 | PubMed ID:3079747 | HubMed [fusion4]
  6. Sierke SL and Koland JG. SH2 domain proteins as high-affinity receptor tyrosine kinase substrates. Biochemistry. 1993 Sep 28;32(38):10102-8. DOI:10.1021/bi00089a028 | PubMed ID:7691170 | HubMed [fusion5]
  7. Nordlund HR, Hytönen VP, Laitinen OH, and Kulomaa MS. Novel avidin-like protein from a root nodule symbiotic bacterium, Bradyrhizobium japonicum. J Biol Chem. 2005 Apr 8;280(14):13250-5. DOI:10.1074/jbc.M414336200 | PubMed ID:15695809 | HubMed [fusion6]
  8. Bradyrhizobium japonicum is an important nitrogenfixing symbiotic bacterium, which can form root nodules on soybeans. These bacteria have a gene encoding a putative avidin- and streptavidin-like protein, which bears an amino acid sequence identity of only about 30% over the core regions with both of them. We produced this protein in Escherichia coli both as the full-length wild type and as a C-terminally truncated core form and showed that it is indeed a high affinity biotin-binding protein that resembles (strept)avidin structurally and functionally. Because of the considerable dissimilarity in the amino acid sequence, however, it is immunologically very different, and polyclonal rabbit and human antibodies toward (strept)avidin did not show significant cross-reactivity with it. Therefore this new avidin, named bradavidin, facilitates medical treatments such as targeted drug delivery, gene therapy, and imaging by offering an alternative tool for use if (strept)avidin cannot be used, because of a deleterious patient immune response for example. In addition to its medical value, bradavidin can be used both in other applications of avidin-biotin technology and as a source of new ideas when creating engineered (strept)avidin forms by changing or combining the desired parts, interface patterns, or specific residues within the avidin protein family. Moreover, the unexpected discovery of bradavidin indicates that the group of new and undiscovered bacterial avidin-like proteins may be both more diverse and more common than hitherto thought.

    [fusion6ab]

All Medline abstracts: PubMed | HubMed


E. coli cell surface display

  1. Jose J. Autodisplay: efficient bacterial surface display of recombinant proteins. Appl Microbiol Biotechnol. 2006 Feb;69(6):607-14. DOI:10.1007/s00253-005-0227-z | PubMed ID:16369779 | HubMed [display1]
  2. Cornelis P. Expressing genes in different Escherichia coli compartments. Curr Opin Biotechnol. 2000 Oct;11(5):450-4. DOI:10.1016/s0958-1669(00)00131-2 | PubMed ID:11024362 | HubMed [display2]
  3. Jung HC, Lebeault JM, and Pan JG. Surface display of Zymomonas mobilis levansucrase by using the ice-nucleation protein of Pseudomonas syringae. Nat Biotechnol. 1998 Jun;16(6):576-80. DOI:10.1038/nbt0698-576 | PubMed ID:9624691 | HubMed [display3]

All Medline abstracts: PubMed | HubMed


Notes on Autodisplay review (display1)

This is a review about the Autodisplay system used to express proteins on the E. coli cell surface. Some of the important features of this system are:

  • Utilizes E.coli-native AIDA-I as scaffold
  • Detection: monoclonal antibodies and protease cleavage sites created
  • Protein unfolded during transport to cell surface.
  • Variety of proteins have been displayed (p.610)
  • Possibly to display catalytically active enzymes.
  • Dimerization of proteins has been observed! (unique to this system); work on tetramers in progress. Protein anchor floats around membrane.
  • Many proteins displayed: ~10^5 without loss of cell viability

The writer claims that the system is superior compared to all other display systems, but he might be biased since he created it.

Notes on expressing genes in different compartments review (display2)

This is a more general review which is actually mostly about cell-surface display techniques. It offers a wider range of options, but came out in 2000, so new options probably have become available.

  • 5 options; a good summary is found on page 3.
    • Porins- Insert protein <= 60 residues
    • Fimbriae- Insert protein <= 15 residues
    • Lipoproteins
    • GPI anchor
    • Beta-autotransporter - same system as that used in display1
  • The latter three were claimed to support large polypeptides. However, looking at a few of the articles seemed to suggest that they actually only tried them out with small polypeptides. The winners appear to be GPI anchors and beta autotransporters, although this might have changed in recent years. See display3 for the use of GPI anchors.

GPI anchor(display3)

I didn't read this one that thoroughly, but the point is that they forced E. coli to express functional levansucrase bound to a GPI anchor, Inp. Using these cells, they successfully converted sucrose to levan, which seems neat. Levansucrase, is about 400 a.a. residues long.

Aptamers

  1. []


Streptavidin

  1. Bayer EA and Wilchek M. Avidin- and streptavidin-containing probes. Methods Enzymol. 1990;184:174-87. DOI:10.1016/0076-6879(90)84272-i | PubMed ID:2201874 | HubMed [sa1]
  2. Sano T and Cantor CR. Expression of a cloned streptavidin gene in Escherichia coli. Proc Natl Acad Sci U S A. 1990 Jan;87(1):142-6. DOI:10.1073/pnas.87.1.142 | PubMed ID:2404273 | HubMed [sa2]
  3. Sano T and Cantor CR. Cooperative biotin binding by streptavidin. Electrophoretic behavior and subunit association of streptavidin in the presence of 6 M urea. J Biol Chem. 1990 Feb 25;265(6):3369-73. PubMed ID:2406253 | HubMed [sa3]
  4. Sano T and Cantor CR. Expression vectors for streptavidin-containing chimeric proteins. Biochem Biophys Res Commun. 1991 Apr 30;176(2):571-7. DOI:10.1016/s0006-291x(05)80222-0 | PubMed ID:2025272 | HubMed [sa4]
  5. Sano T, Pandori MW, Chen X, Smith CL, and Cantor CR. Recombinant core streptavidins. A minimum-sized core streptavidin has enhanced structural stability and higher accessibility to biotinylated macromolecules. J Biol Chem. 1995 Nov 24;270(47):28204-9. DOI:10.1074/jbc.270.47.28204 | PubMed ID:7499314 | HubMed [sa5]
  6. Sano T, Smith CL, and Cantor CR. Expression and purification of recombinant streptavidin-containing chimeric proteins. Methods Mol Biol. 1997;63:119-28. DOI:10.1385/0-89603-481-X:119 | PubMed ID:9113646 | HubMed [sa6]
  7. Szafranski P, Mello CM, Sano T, Smith CL, Kaplan DL, and Cantor CR. A new approach for containment of microorganisms: dual control of streptavidin expression by antisense RNA and the T7 transcription system. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1059-63. DOI:10.1073/pnas.94.4.1059 | PubMed ID:9037005 | HubMed [sa7]
  8. Sano T, Vajda S, Smith CL, and Cantor CR. Engineering subunit association of multisubunit proteins: a dimeric streptavidin. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6153-8. DOI:10.1073/pnas.94.12.6153 | PubMed ID:9177186 | HubMed [sa8]
  9. Kaplan DL, Mello C, Sano T, Cantor C, and Smith C. Streptavidin-based containment systems for genetically engineered microorganisms. Biomol Eng. 1999 Dec 31;16(1-4):135-40. DOI:10.1016/s1050-3862(99)00040-6 | PubMed ID:10796996 | HubMed [sa9]
  10. Sano T and Cantor CR. Streptavidin-containing chimeric proteins: design and production. Methods Enzymol. 2000;326:305-11. DOI:10.1016/s0076-6879(00)26061-8 | PubMed ID:11036649 | HubMed [sa10]
  11. Farlow SJ, Wang RJ, Pandori MW, and Sano T. A chimera of a gelatinase inhibitor peptide with streptavidin as a bifunctional tumor targeting reagent. FEBS Lett. 2002 Apr 10;516(1-3):197-200. DOI:10.1016/s0014-5793(02)02565-6 | PubMed ID:11959132 | HubMed [sa11]
  12. McDevitt TC, Nelson KE, and Stayton PS. Constrained cell recognition peptides engineered into streptavidin. Biotechnol Prog. 1999 May-Jun;15(3):391-6. DOI:10.1021/bp990043n | PubMed ID:10356256 | HubMed [sa12]
  13. Farlow SJ, Wang RJ, Pandori MW, and Sano T. A chimera of a gelatinase inhibitor peptide with streptavidin as a bifunctional tumor targeting reagent. FEBS Lett. 2002 Apr 10;516(1-3):197-200. DOI:10.1016/s0014-5793(02)02565-6 | PubMed ID:11959132 | HubMed [sa13]
  14. Nordlund HR, Hytönen VP, Laitinen OH, and Kulomaa MS. Novel avidin-like protein from a root nodule symbiotic bacterium, Bradyrhizobium japonicum. J Biol Chem. 2005 Apr 8;280(14):13250-5. DOI:10.1074/jbc.M414336200 | PubMed ID:15695809 | HubMed [sa14]
  15. Tahiri-Alaoui A, Frigotto L, Manville N, Ibrahim J, Romby P, and James W. High affinity nucleic acid aptamers for streptavidin incorporated into bi-specific capture ligands. Nucleic Acids Res. 2002 May 15;30(10):e45. DOI:10.1093/nar/30.10.e45 | PubMed ID:12000850 | HubMed [sa15]
  16. Lemercier G and Johnsson K. Chimeric streptavidins with reduced valencies. Nat Methods. 2006 Apr;3(4):247-8. DOI:10.1038/nmeth0406-247 | PubMed ID:16554826 | HubMed [sa16]

All Medline abstracts: PubMed | HubMed



Related articles..

  1. Valls M, González-Duarte R, Atrian S, and De Lorenzo V. Bioaccumulation of heavy metals with protein fusions of metallothionein to bacterial OMPs. Biochimie. 1998 Oct;80(10):855-61. DOI:10.1016/s0300-9084(00)88880-x | PubMed ID:9893944 | HubMed [other1]


Cd2+ binding

other1 is an old review article I came across talking about expressing metallothioneins on the cell surface of E. coli; these things bind Cd2+, so those interested in pollution cleanup might want to take a look.